Astellas Pharma, Inc. (ALPMF)
15.35
+0.10
(+0.66%)
USD |
OTCM |
Oct 06, 16:00
Astellas Pharma Enterprise Value : 29.66B for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 29.66B |
| October 05, 2026 | 29.48B |
| October 02, 2026 | 27.90B |
| October 01, 2026 | 28.44B |
| September 30, 2026 | 28.44B |
| September 29, 2026 | 30.46B |
| September 28, 2026 | 31.45B |
| September 25, 2026 | 29.43B |
| September 24, 2026 | 29.12B |
| September 23, 2026 | 30.70B |
| September 22, 2026 | 29.59B |
| September 21, 2026 | 29.48B |
| September 18, 2026 | 26.97B |
| September 17, 2026 | 26.97B |
| September 16, 2026 | 26.97B |
| September 15, 2026 | 30.82B |
| September 14, 2026 | 30.11B |
| September 11, 2026 | 30.55B |
| September 10, 2026 | 29.84B |
| September 09, 2026 | 30.20B |
| September 08, 2026 | 30.46B |
| September 04, 2026 | 29.21B |
| September 03, 2026 | 28.69B |
| September 02, 2026 | 28.69B |
| September 01, 2026 | 28.69B |
| Date | Value |
|---|---|
| August 31, 2026 | 30.64B |
| August 28, 2026 | 29.21B |
| August 27, 2026 | 31.72B |
| August 26, 2026 | 27.24B |
| August 25, 2026 | 30.55B |
| August 24, 2026 | 30.55B |
| August 21, 2026 | 31.27B |
| August 20, 2026 | 31.63B |
| August 19, 2026 | 29.39B |
| August 18, 2026 | 29.39B |
| August 17, 2026 | 30.46B |
| August 14, 2026 | 31.09B |
| August 13, 2026 | 26.25B |
| August 12, 2026 | 30.91B |
| August 11, 2026 | 30.91B |
| August 10, 2026 | 28.85B |
| August 07, 2026 | 30.91B |
| August 06, 2026 | 25.53B |
| August 05, 2026 | 25.17B |
| August 04, 2026 | 25.17B |
| August 03, 2026 | 26.83B |
| July 31, 2026 | 28.58B |
| July 30, 2026 | 29.66B |
| July 29, 2026 | 29.66B |
| July 28, 2026 | 27.86B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 84.77B |
| Daiichi Sankyo Co., Ltd. | 30.92B |
| Eisai Co., Ltd. | 8.174B |
| Chugai Pharmaceutical Co., Ltd. | 57.63B |
| Santen Pharmaceutical Co., Ltd. | 2.989B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 889.54M |
| Revenue (Quarterly) | 4.022B |
| Total Expenses (Quarterly) | 3.133B |
| EPS Diluted (Quarterly) | 0.4955 |
| Gross Profit Margin (Quarterly) | 75.29% |
| Profit Margin (Quarterly) | 22.12% |
| Earnings Yield | 8.54% |
| Operating Earnings Yield | 11.60% |
| Normalized Earnings Yield | 8.541 |